Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Transplantation. 2013 Jul 15;96(1):34–41. doi: 10.1097/TP.0b013e318295c025

FIGURE 3. Synergy of anti-ICOS and CTLA4-Ig in suppressing MLR.

FIGURE 3

Anti-ICOS was added to 7-day MLR at 0–200 nM in the presence or absence of CTLA4-Ig at 1 or 5 nM (left panel), or presence or absence of CSP at 0.8–8 nM. The effect of CTLA4-Ig or CSP alone on the MLR is indicated by the black solid bars (positive control). Results are presented in CPM of 3H-thymidine incorporation and representative of 5 experiements).